Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.76 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229617 | 0.88 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18237036 | 0.88 | HDAC6 (0.81) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18229505 | 0.87 | HDAC6 (0.71) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18229494 | 0.87 | HDAC6 (0.79) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18229509 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18229590 | 0.87 | HDAC6 (0.79) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18237054 | 0.86 | HDAC6 (0.95) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18237041 | 0.86 | HDAC6 (0.76) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18237037 | 0.86 | HDAC6 (0.77) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18229540 | 0.86 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294715-B1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2020-05-06 | — | — | EP | claimed |
| EP-3294715-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | Kancera AB (SE) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180472-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2016-11-17 | — | — | WO | claimed |
| EP-3294715-B1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2020-05-06 | — | — | EP | disclosed |
| US-20180110755-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2018-04-26 | — | — | US | disclosed |
| WO-2016180472-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110755-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC3 11/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.